U.S. Energy Boom Ke...
Health Care: Drugs
Galena Biopharma Inc (GALE: NASDAQ)
$2.60 0.02 | 0.78%
05/23/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 2.58 |
| 52 Week High | 3.00 |
| 52 Week Low | 1.17 |
| Avg. Daily Vol. (Mil) | 2.03 |
| Beta (3 year) | 1.59 |
| Share Related Items | |
| Mkt Cap (Mil) | 215.34 |
| Shares Out (Mil) | 83.46 |
| Float (Mil) | 82.39 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.00 |
| Current Ratio | 1.00 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 9.24 |
| Price/Cash Flow | -11.00 |
| Per Share Data | |
| Earnings | -0.28 |
| Sales | 0.00 |
| Book Value | 0.28 |
| Cash Flow | -0.23 |
| Business Summary | |
|---|---|
| Galena Biopharma Inc is a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics. | |
| General Information | |
| 310 N. State Street
Suite 208 Lake Oswego, OR 97034 |
|
| www.galenabiopharma.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 12 | |
| CEO: Dr. Mark J. Ahn, PhD | |
| Short Interest | |
| Current Month (Mil) | 11.62 |
| Previous Month (Mil) | 10.10 |
| Short Interest Ratio (Days) | 4.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -31.70 |
| Return on Investments | -83.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with GALE
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserMy Portfolio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
Latest GALE Headlines from TheStreet
- Galena Biopharma To Present At The 2013 Marcum MicroCap Conference 05.23.13 | 07:05 am
- VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial Results 05.09.13 | 04:05 pm
- Galena Biopharma Poster Presentation At The American Pain Society 32nd Annual Scientific Meeting 05.09.13 | 07:05 am
- William L. Ashton Joins Galena Biopharma's Board Of Directors 05.01.13 | 07:05 am
- Galena Biopharma To Present At The 12th Annual Needham Healthcare Conference 04.24.13 | 07:04 am
- Galena Biopharma To Present At The 2013 BIO International Convention 04.16.13 | 07:04 am
- Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy 04.12.13 | 06:04 am
- 4 Biotech Stocks Under $10 Making Big Moves 04.09.13 | 02:04 pm
- Galena Biopharma To Present At The 20th Annual Future Leaders In The Biotech Industry Conference 03.29.13 | 07:03 am
- 4 Stocks Under $10 Making Big Moves 03.26.13 | 02:03 pm
Press Releases for GALE
- Frost & Sullivan Applauds Galena Biopharma For Its Breakthrough Breast Cancer Vaccine, NeuVaxâ¿¢ - PR Newswire 03.12.13 | 07:03 am
- Galena Biopharma, Inc. Investor Presentation Now Available For On-demand Viewing At RetailInvestorConferences.com - PR Newswire 06.12.12 | 09:06 am
- Galena Biopharma, Inc. To Webcast, Live, At RetailInvestorConferences.com On June 7th - PR Newswire 06.06.12 | 09:06 am
- RXi Pharmaceuticals’ Common Stock To Commence Trading Under The Symbol “RXII” - Business Wire 05.10.12 | 06:05 am
Partner Headlines for GALE
- Galena Biopharma: Will Developments Continue In 2013? - Seeking Alpha 04.03.13 | 09:04 am
- What Makes For A Market Leading Return In Biotechnology? - Seeking Alpha 01.22.13 | 09:01 am
- Galena Pulls Back While Analysts Rush To Its Defense - Seeking Alpha 12.17.12 | 08:12 am
- Biotech Under The Electron Microscope: What's In The Pipeline And Lessons To Be Learned - Seeking Alpha 12.16.12 | 08:12 am
- Morning Market Movers - Benzinga 12.04.12 | 09:12 am
- UPDATE: Aegis Capital Corp. Initiates Coverage on Galena Biopharma with Buy Rating, $6 PT - Benzinga 11.28.12 | 09:11 am
- A Gold Mine In Biotechnology: The Companies Poised To Benefit - Seeking Alpha 09.04.12 | 09:09 am
- Reassessing & Continuing To Monitor Portfolios For Success - Seeking Alpha 07.30.12 | 09:07 am
- Are Galena Biopharma's Largest Shareholders Giddy About Their Drug Trial Results? - Wall St. Cheat Sheet 06.21.12 | 11:06 am
- Galena Biopharma Announces Public Offering of Common Stock - Benzinga 04.04.12 | 04:04 pm
